Kura Oncology (KURA) Total Non-Current Liabilities (2014 - 2026)
Kura Oncology (KURA) posted quarterly Total Non-Current Liabilities of $541.2 million for Q1 2026, up 43.48% year-over-year from $377.2 million in Q1 2025, and down 3.53% quarter-over-quarter from $561.1 million in Q4 2025.
Kura Oncology (KURA) Total Non-Current Liabilities (2014 - 2026) Analysis & Trends
Kura Oncology (KURA) has reported Total Non-Current Liabilities for 13 consecutive years, with $541.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 43.48% year-over-year to $541.2 million; the TTM figure through Mar 2026 stood at $541.2 million (up 43.48% YoY), while the FY2025 annual figure was $561.1 million, up 62.76% from the prior year.
- Total Non-Current Liabilities fell to $541.2 million in Q1 2026 per KURA's latest filing, from $561.1 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $561.1 million in Q4 2025 and bottomed at $21.5 million in Q2 2022.
- Historically, Total Non-Current Liabilities has averaged $177.5 million across 5 years, with a median of $47.9 million in 2024.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities plunged 35.45% — and 2025, when it surged 687.96%.
- Kura Oncology's Total Non-Current Liabilities stood at $35.8 million in 2022, then surged by 42.49% to $51.0 million in 2023, then soared by 576.5% to $344.7 million in 2024, then soared by 62.76% to $561.1 million in 2025, then retreated by 3.53% to $541.2 million in 2026.
- Business Quant data shows KURA's Total Non-Current Liabilities at $541.2 million in Q1 2026, $561.1 million in Q4 2025, and $403.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Kura Oncology | 966.11 Mn | 966.11 Mn | 20.63 Mn | 535.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 535.74 Mn |
| Mar 31, 2026 | 541.23 Mn |
| Dec 31, 2025 | 561.06 Mn |
| Sep 30, 2025 | 403.86 Mn |
| Jun 30, 2025 | 374.34 Mn |
| Mar 31, 2025 | 377.22 Mn |
| Dec 31, 2024 | 344.72 Mn |
| Sep 30, 2024 | 53.60 Mn |
| Jun 30, 2024 | 47.87 Mn |
| Mar 31, 2024 | 47.87 Mn |
| Dec 31, 2023 | 50.96 Mn |
| Sep 30, 2023 | 43.27 Mn |
| Jun 30, 2023 | 34.60 Mn |
| Mar 31, 2023 | 30.44 Mn |
| Dec 31, 2022 | 35.76 Mn |
| Sep 30, 2022 | 27.83 Mn |
| Jun 30, 2022 | 21.48 Mn |
| Mar 31, 2022 | 21.84 Mn |
| Dec 31, 2021 | 27.07 Mn |
| Sep 30, 2021 | 27.03 Mn |